EFHD1 Antibody
Description
Introduction to EFHD1 Antibody
EFHD1 antibodies are immunoglobulins specifically developed to target the EFHD1 protein (EF-hand domain family, member D1), also known as Swiprosin-2. These antibodies serve as critical research tools for investigating EFHD1's expression, localization, and function in biological systems. The target protein EFHD1 is a calcium-binding mitochondrial protein with a calculated molecular weight of approximately 27 kDa and comprises 239 amino acids . Understanding EFHD1 antibodies requires some context about their target protein, which contains EF-hand domains (calcium-binding motifs) and plays roles in mitochondrial function, particularly in reactive oxygen species (ROS) regulation and calcium sensing .
Types and Characteristics of EFHD1 Antibodies
EFHD1 antibodies are available in several formats, each with distinct properties suitable for different research applications:
Classification by Clonality
EFHD1 antibodies are categorized based on their clonality:
Polyclonal Antibodies: Most commercially available EFHD1 antibodies are polyclonal, produced by immunizing rabbits with synthetic peptides or fusion proteins derived from human EFHD1 . These antibodies recognize multiple epitopes on the EFHD1 protein, providing robust detection but potentially variable specificity between lots.
Monoclonal Antibodies: Several monoclonal antibodies against EFHD1 have been developed, including mouse monoclonal antibodies such as clone 5K1 and 3G2 . These antibodies target specific epitopes with high consistency between batches.
Host Species and Reactivity
Most EFHD1 antibodies are developed in rabbits, though some mouse-derived monoclonal antibodies are available . Their reactivity profiles typically include:
This cross-species reactivity is valuable for comparative studies and translational research using animal models.
Immunogen Design
EFHD1 antibodies are generated using various immunogen strategies:
-
Synthetic peptides derived from specific regions of human EFHD1
-
Epitope-targeted approaches focusing on specific amino acid sequences
For example, Novus Biologicals' antibody was raised against a 14-amino acid synthetic peptide near the amino terminus of human EFHD1 .
Validation Methods for EFHD1 Antibodies
Rigorous validation is essential for ensuring antibody specificity and reliability in research applications. EFHD1 antibodies undergo several validation procedures:
Genetic Validation
One of the most stringent validation approaches involves testing antibodies against tissues from EFHD1-knockout models. In one study, an EFHD1 polyclonal antibody was developed and validated by testing against Efhd1−/− mouse tissue, confirming its specificity . This validation method provides definitive evidence of antibody specificity.
Standard Validation Methods
Commercial EFHD1 antibodies typically undergo multiple validation techniques:
-
Western Blot Validation: Confirming antibody binding to a protein of the expected molecular weight (27 kDa for EFHD1)
-
Immunohistochemical Validation: Demonstrating appropriate tissue staining patterns in tissues known to express EFHD1, such as adrenal and lung tissues
-
Cross-reactivity Testing: Assessment of binding specificity across multiple species and potential cross-reactivity with related proteins
Enhanced Validation Approaches
Some EFHD1 antibodies undergo enhanced validation procedures:
-
Independent Antibody Validation: Comparing staining patterns of multiple antibodies targeting different epitopes of EFHD1
-
Orthogonal Validation: Correlating antibody staining with other measures of EFHD1 expression
-
Recombinant Expression Validation: Testing antibody specificity against recombinantly expressed EFHD1
These rigorous validation methods ensure that research findings using EFHD1 antibodies are reliable and reproducible.
Applications of EFHD1 Antibodies in Research
EFHD1 antibodies serve diverse research applications, enabling investigation of this protein's expression, localization, and function:
Western Blotting
Western blotting represents one of the most common applications for EFHD1 antibodies, allowing detection and semi-quantitative analysis of EFHD1 protein in tissue or cell lysates. Several commercial antibodies are validated for this application . In research studies, EFHD1 antibodies have been used at dilutions ranging from 1:500 to 1:1000 for Western blot analysis .
Immunohistochemistry
EFHD1 antibodies enable visualization of the protein's expression and distribution in tissue sections. Several antibodies are validated for immunohistochemistry, particularly for paraffin-embedded sections (IHC-P) . For example, Abcam's EFHD1 antibody (ab118599) has been used at 5 μg/ml concentration for staining in formalin-fixed, paraffin-embedded human adrenal and lung tissues .
Immunofluorescence
Immunofluorescence applications allow researchers to determine the subcellular localization of EFHD1. Multiple antibodies are validated for this technique, including those suitable for paraffin-embedded sections (IF-P) . This application is particularly valuable for confirming EFHD1's mitochondrial localization.
ELISA and Other Applications
Several EFHD1 antibodies are validated for Enzyme-Linked Immunosorbent Assay (ELISA), enabling quantitative measurement of EFHD1 protein levels . Additional applications include immunoprecipitation and immunocytochemistry, though these are supported by fewer commercial antibodies .
EFHD1 Antibodies in Scientific Discovery
EFHD1 antibodies have facilitated significant research findings that advance our understanding of this protein's biological functions:
Mitochondrial Function Research
EFHD1 antibodies have been instrumental in studies characterizing EFHD1's role in mitochondrial function. Research has established that EFHD1 acts as a calcium sensor for mitochondrial flash (mitoflash) activation, an event characterized by stochastic bursts of superoxide production . These discoveries help explain EFHD1's role in regulating reactive oxygen species (ROS) in mitochondria.
Cardiac Research
In cardiac research, EFHD1 antibodies have enabled investigations revealing that Efhd1−/− mice display no overt cardiac pathology under normal conditions but show reduced basal ROS levels and mitoflash activity . Remarkably, these knockout mice demonstrate resistance to hypoxia and cell death due to ischemia, suggesting potential cardioprotective effects of EFHD1 inhibition . This finding has significant implications for developing treatments for cardiac ischemia-reperfusion injury.
Actin Interactions
Research utilizing EFHD1 antibodies has demonstrated that EFHD1 possesses calcium-independent β-actin-binding and calcium-dependent β-actin-bundling activities . These findings suggest that EFHD1 may contribute to the calcium-dependent regulation of mitochondrial morphology through interactions with the cytoskeleton .
Technical Considerations for EFHD1 Antibody Usage
Researchers working with EFHD1 antibodies should consider several technical factors to optimize experimental outcomes:
Optimal Working Conditions
The optimal working conditions for EFHD1 antibodies vary depending on the specific application and antibody:
-
Western Blotting: Typically used at dilutions ranging from 1:500 to 1:1000
-
Immunohistochemistry: Concentrations around 5 μg/ml have been reported for formalin-fixed, paraffin-embedded tissues
-
ELISA: Optimal dilutions must be determined experimentally for each antibody
Troubleshooting Common Issues
When working with EFHD1 antibodies, researchers may encounter several challenges:
-
Non-specific Binding: Optimize blocking conditions, antibody dilutions, and washing protocols
-
Weak Signals: Consider longer incubation times, higher antibody concentrations, or more sensitive detection systems
-
High Background: Implement more stringent washing steps and optimize blocking conditions
-
Variable Results: Standardize sample preparation methods and consider lot-to-lot variations in antibody performance
Future Perspectives
The development and application of EFHD1 antibodies continue to evolve, with several promising directions:
Novel EFHD1 Antibody Formats
Future antibody development may focus on:
-
Recombinant antibody formats with improved specificity
-
Antibodies targeting specific post-translational modifications of EFHD1
-
Antibodies suitable for super-resolution microscopy applications
Therapeutic Potential
The finding that Efhd1−/− mice are resistant to hypoxic injury suggests that inhibition of EFHD1 may have cardioprotective effects . This creates potential for developing antibody-based therapeutics or diagnostics targeting EFHD1 in cardiovascular diseases.
Biomarker Applications
As research into EFHD1's role in various diseases progresses, EFHD1 antibodies may find applications in biomarker detection and disease monitoring, particularly in conditions involving mitochondrial dysfunction.
Product Specs
Target Background
- EFHD1 functions as a novel mitochondrial Ca(2+) sensor responsible for Ca(2+)-dependent activation of mitoflashes. PMID: 26975899
- Analysis of methylation of PPP1R3C alone or in combination with EFHD1 in plasma DNA demonstrated high sensitivity and specificity in colorectal cancer (CRC) detection. This approach may serve as a valuable detection method for CRC, particularly for early-stage tumors. PMID: 24861485
- Cloning of novel mouse genes associated with neuronal function, including Efhd1. PMID: 12270117
Q&A
What is EFHD1 and what cellular functions is it involved in?
EFHD1 (EF-Hand Domain Family Member D1) is a calcium-binding protein containing EF-hand domains. It plays roles in calcium homeostasis and signaling pathways. EFHD1 is predominantly expressed in mitochondria and has been implicated in mitochondrial function and cellular metabolism. It's becoming increasingly recognized for its potential role in cancer progression, particularly in the tumor microenvironment. Recent studies have identified its overexpression in gastric cancer tissues compared to non-cancerous samples, suggesting its involvement in tumor development and progression .
What are the most effective applications for EFHD1 antibodies in research?
EFHD1 antibodies have demonstrated effectiveness across multiple research applications. They are primarily utilized in Western Blotting (WB), Immunohistochemistry with paraffin-embedded sections (IHC-p), and Immunofluorescence (IF). These techniques allow researchers to detect and quantify EFHD1 expression in various tissue and cell samples. Multiplex immunohistochemistry (mIHC) has been particularly valuable for investigating the relationship between EFHD1 expression and immune cell infiltration in the tumor microenvironment .
How do I select the appropriate EFHD1 antibody for my specific research application?
Selection should be based on several key factors:
-
Target species reactivity: Ensure the antibody reacts with your species of interest (human, mouse, rat)
-
Application compatibility: Verify the antibody is validated for your intended application (WB, IHC, IF)
-
Clonality requirements: Choose between polyclonal (broader epitope recognition) or monoclonal (higher specificity) based on your experiment
-
Epitope recognition: Select antibodies targeting specific amino acid regions relevant to your research question
-
Host species: Consider the host species to avoid cross-reactivity in multi-labeling experiments
For studies involving the tumor microenvironment, antibodies validated for paraffin-embedded sections have proven particularly valuable in recent research .
What are the optimal sample preparation protocols for EFHD1 antibody applications?
For optimal results with EFHD1 antibodies:
In Western Blotting:
-
Use protein extraction methods that preserve native protein structure
-
Include protease inhibitors to prevent degradation
-
Optimize protein loading (typically 20-50μg total protein)
-
Perform proper blocking (3-5% BSA or milk) to reduce background
In Immunohistochemistry:
-
Ensure proper fixation (10% neutral-buffered formalin recommended)
-
Perform heat-induced epitope retrieval (citrate buffer pH 6.0 or EDTA buffer pH 9.0)
-
Optimize antibody dilution through titration experiments
-
Include appropriate positive and negative controls
For Immunofluorescence:
-
Maintain strict temperature control during fixation
-
Use appropriate permeabilization agents
-
Consider signal amplification systems for low abundance targets
How can I implement multiplex immunohistochemistry to study EFHD1 in relation to tumor-infiltrating immune cells?
Multiplex immunohistochemistry (mIHC) is a sophisticated technique that allows simultaneous detection of multiple markers, including EFHD1 and immune cell markers, in a single tissue section. Implementation involves:
-
Sequential antibody labeling: Apply and visualize antibodies one by one with intermediate stripping steps
-
Spectral unmixing: Use multispectral imaging systems to separate overlapping fluorescent signals
-
Proper panel design: Combine EFHD1 antibody with markers for immune cells (e.g., CD66b for neutrophils, CD68/CD86 for M1 macrophages, CD68/CD163 for M2 macrophages)
-
Image analysis: Employ computational methods to quantify marker expression and colocalization
Recent studies have successfully used this approach to demonstrate significant correlation between EFHD1 expression and CD66b+ neutrophil infiltration in both intratumoral (r = 0.420, P < 0.001) and stromal (r = 0.367, P < 0.001) regions of gastric cancer microenvironment .
What are the current methods for analyzing the relationship between EFHD1 expression and clinical outcomes?
Advanced analytical methods include:
These methods have revealed EFHD1 as an independent prognostic predictor (HR = 2.262, P < 0.001) in gastric cancer patients, with high expression correlating with increased tumor size and advanced TNM staging .
How can I design experiments to investigate the mechanistic role of EFHD1 in tumor progression?
A comprehensive experimental design should include:
-
In vitro modulation of EFHD1 expression:
-
Gene knockdown using siRNA or CRISPR-Cas9
-
Overexpression using suitable vectors
-
Analysis of resulting phenotypes (proliferation, migration, invasion)
-
-
Pathway analysis:
-
Phosphoproteomic analysis to identify downstream effectors
-
Co-immunoprecipitation to identify binding partners
-
Calcium signaling assays to assess functional impact
-
-
In vivo models:
-
Xenograft models with EFHD1-modulated cell lines
-
Analysis of tumor growth, metastasis, and immune infiltration
-
Correlation with observations from patient samples
-
-
Translational validation:
What approaches can be used to study the calcium-binding properties of EFHD1 and their functional significance?
To study calcium-binding properties and their functional significance:
-
Structural analysis:
-
Circular dichroism spectroscopy to assess conformational changes upon calcium binding
-
Isothermal titration calorimetry to determine binding affinity and stoichiometry
-
NMR spectroscopy to map calcium-binding regions
-
-
Functional assays:
-
Calcium flux measurements using fluorescent indicators
-
Mitochondrial calcium uptake assays
-
Calcium-dependent protein interaction studies
-
-
Mutational analysis:
How do I resolve conflicting data between EFHD1 mRNA and protein expression levels?
Conflicts between mRNA and protein expression are common in research. To resolve:
-
Validate with multiple techniques:
-
Compare protein detection using different antibodies targeting distinct epitopes
-
Employ alternative RNA quantification methods (RNA-seq, qRT-PCR)
-
Use absolute quantification methods when possible
-
-
Consider biological factors:
-
Post-transcriptional regulation (miRNAs, RNA stability)
-
Post-translational modifications affecting antibody recognition
-
Protein turnover rates differing from mRNA stability
-
-
Analyze subcellular localization:
-
Fractionation studies to assess protein distribution
-
Immunofluorescence to visualize localization patterns
-
Comparison with mRNA localization if applicable
-
Research has highlighted the non-linear relationship between transcriptomic data and proteome, emphasizing the importance of protein-level validation when working with EFHD1 .
What are common causes of non-specific binding with EFHD1 antibodies and how can they be mitigated?
Common causes and mitigation strategies include:
-
Cross-reactivity with similar proteins:
-
Use highly specific monoclonal antibodies
-
Validate specificity using knockout/knockdown controls
-
Perform peptide competition assays
-
-
Inadequate blocking:
-
Optimize blocking reagents (BSA, milk, commercial blockers)
-
Increase blocking time and concentration
-
Consider alternative blocking agents for specific applications
-
-
Suboptimal antibody dilution:
-
Perform careful titration experiments
-
Start with manufacturer's recommended dilution and adjust as needed
-
Use appropriate antibody diluents with stabilizers
-
-
Sample-specific factors:
How should I interpret EFHD1 expression patterns in relation to tumor-infiltrating immune cells?
Interpretation requires careful consideration of:
Recent research showed EFHD1 expression significantly correlates with CD66b+ neutrophils, with moderate associations with macrophages and dendritic cells, suggesting potential functional interactions in the tumor microenvironment .
What statistical approaches are most appropriate for analyzing EFHD1 expression data across different experimental conditions?
| Data Type | Recommended Statistical Analysis | Assumptions | Example Application |
|---|---|---|---|
| Continuous expression data (normal distribution) | Student's t-test, ANOVA, Pearson correlation | Normality, homogeneity of variance | Comparing EFHD1 expression between tumor and normal tissues |
| Continuous expression data (non-normal) | Mann-Whitney U test, Kruskal-Wallis, Spearman correlation | No normality assumption | Correlating EFHD1 with immune cell infiltration |
| Categorical data | Chi-square test, Fisher's exact test | Adequate sample size, independence | Associating EFHD1 expression levels with clinicopathological features |
| Survival data | Kaplan-Meier with log-rank test, Cox regression | Proportional hazards assumption for Cox | Analyzing prognostic value of EFHD1 expression |
| Multivariate data | Principal component analysis, clustering | Variable interdependence, appropriate distance metrics | Identifying expression patterns across multiple markers |
What is the current understanding of EFHD1's role in gastric cancer progression and the tumor microenvironment?
Recent studies have significantly advanced our understanding of EFHD1 in gastric cancer:
-
Expression patterns:
-
EFHD1 mRNA is overexpressed in gastric cancer tissues compared to non-cancerous samples (t = 6.460, P < 0.001)
-
Protein-level overexpression has been confirmed through multiplex immunohistochemistry (t = 6.246, P < 0.001)
-
-
Clinical correlations:
-
High EFHD1 expression associates with increased tumor size (χ² = 19.120, P < 0.001)
-
Advanced TNM staging correlates with elevated EFHD1 (χ² = 14.468, P = 0.002)
-
EFHD1 serves as an independent prognostic predictor (HR = 2.262, P < 0.001)
-
-
Immune cell interactions:
How can EFHD1 antibodies be utilized in research toward potential therapeutic applications?
EFHD1 antibodies enable several research approaches with therapeutic implications:
-
Biomarker development:
-
Validation of EFHD1 as a prognostic biomarker in diverse cancer types
-
Development of diagnostic assays for clinical applications
-
Monitoring treatment response through EFHD1 expression
-
-
Target validation:
-
Determining functional significance through neutralizing antibodies
-
Evaluating effects of EFHD1 inhibition on tumor growth and immune infiltration
-
Identifying patient subgroups likely to benefit from EFHD1-targeted therapies
-
-
Therapeutic antibody development:
-
Screening for antibodies that modulate EFHD1 function
-
Developing antibody-drug conjugates targeting EFHD1-expressing cells
-
Engineering bispecific antibodies linking EFHD1 with immune effector cells
-
-
Combination therapy research:
What are the technical challenges in studying EFHD1 in the context of calcium signaling and mitochondrial function?
Key technical challenges include:
-
Temporal and spatial resolution:
-
Capturing transient calcium signals requires sophisticated imaging techniques
-
Distinguishing mitochondrial EFHD1 from other subcellular pools
-
Monitoring dynamic processes in live cells versus fixed specimens
-
-
Physiological relevance:
-
Maintaining calcium homeostasis in experimental systems
-
Avoiding artifacts from overexpression systems
-
Translating in vitro findings to in vivo contexts
-
-
Methodological limitations:
-
Limited sensitivity of calcium indicators for subtle changes
-
Challenges in manipulating mitochondrial proteins specifically
-
Difficulty in separating direct from indirect effects in complex signaling cascades
-
-
Analytical complexity:
How might EFHD1 research contribute to our understanding of immune regulation in the tumor microenvironment?
EFHD1 research offers several promising avenues for understanding immune regulation:
-
Neutrophil biology:
-
Investigating mechanisms underlying the correlation between EFHD1 and neutrophil infiltration
-
Examining neutrophil phenotypes in EFHD1-high versus EFHD1-low tumors
-
Studying neutrophil extracellular traps (NETs) in relation to EFHD1 expression
-
-
Macrophage polarization:
-
Exploring EFHD1's association with both M1 and M2 macrophage populations
-
Investigating potential direct effects on macrophage polarization
-
Assessing impact on macrophage-mediated immunosuppression
-
-
Dendritic cell function:
-
Examining antigen presentation capacity in relation to EFHD1 expression
-
Studying migration and maturation of dendritic cells
-
Investigating T cell priming efficiency
-
-
Therapeutic implications:
